10 mg CBL-514 per injection + 15 mg CBL-514 per injection
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dercum's Disease
Conditions
Dercum's Disease
Trial Timeline
Oct 3, 2022 → Apr 3, 2023
NCT ID
NCT05387733About 10 mg CBL-514 per injection + 15 mg CBL-514 per injection
10 mg CBL-514 per injection + 15 mg CBL-514 per injection is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Dercum's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05387733. Target conditions include Dercum's Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05387733 | Phase 2 | Completed |
Competing Products
1 competing product in Dercum's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CBL-514 injection + 0.9% Sodium chloride | Caliway Biopharmaceuticals | Phase 2 | 51 |